Evidence-based summary of culture-based universal screening, intrapartum antibiotic prophylaxis indications, dosing regimens, and penicillin allergy algorithm in preventing early-onset neonatal GBS disease.
⚕️ Target audience: This clinical review is intended for physicians and healthcare professionals; It is a summary of current literature and guidelines for educational purposes. Clinical decisions should be made based on patient-specific evaluation and applicable institutional protocols.
Group B Streptococcus (GBS; Streptococcus agalactiae ) is an encapsulated, Gram-positive coccus found as a commensal of the gastrointestinal and genital tract in approximately 15–40% of pregnant women (UpToDate 2026; ACOG CO 797, 2020). Colonization is asymptomatic for mothers; However, colonization at the time of birth is the critical determinant of neonatal GBS disease, which is the most common cause of invasive bacterial infection in infants less than 90 days of age. Vertical (mother to baby) transmission occurs mainly by passage of GBS from the vagina into the amniotic fluid during labor or rupture of membranes, as well as by contact of the fetus with vaginal GBS in intact membranes and during passage through the birth canal.
The disease is divided into two main phenotypes according to the time of onset:
Randomized clinical trials in the mid-1980s demonstrated that intrapartum administration of intravenous penicillin G or ampicillin to colonized pregnant women protected newborns from EOGBS (Boyer & Gotoff, NEJM 1986). Based on this evidence, widespread universal screening and IAP implementation in the United States has reduced the incidence of EOGBS from 1.5/1000 live births in 1993 to 0.18/1000 by 2022 (UpToDate 2026; CDC). However, the incidence is still several times higher in black infants (0.36/1000), a significant indicator of inequality.
ACOG and CDC prefer a culture-based universal screening approach to a risk factor-based approach in preventing EOGBS (ACOG CO 797, 2020). The main problem of the risk factor-based approach is that approximately half of EOGBS cases occur in pregnant women without any identifiable risk factors or the risk factor is detected too late for effective prophylaxis.
A 2020 meta-analysis found that universal screening resulted in a 57% reduction in EOGBS compared to risk-based protocols (RR 0.43, 95% CI 0.32–0.56) and a 69% reduction compared to no policy (RR 0.31, 95% CI 0.11–0.84); showed that risk-based protocols were not significantly more effective (RR 0.86, 95% CI 0.61–1.20) than no policy (UpToDate 2026). Importantly, universal screening does not lead to significantly greater antibiotic use compared to risk-based protocols (31% versus 29%).
GBS rectovaginal screening culture is applied to all pregnant women between 36 0/7 – 37 6/7 weeks of gestation, with the following exceptions (ACOG CO 797, 2020). This window replaces the pre-2019 recommendation of 35–37 weeks. The rationale for timing is this: since colonization can be temporary/intermittent, culture is taken close to term; This window ensures that results are available before most pregnant women go into labor and remain valid for those who do not labor until 41 0/7 weeks — because culture results are predictive of GBS status for approximately 5 weeks. The negative predictive value of a culture taken ≤5 weeks before birth is 95–98% and declines after 5 weeks; therefore, if more than 5 weeks have passed since the previous negative result, the culture is repeated (UpToDate 2026).
Correct sampling technique is critical for sensitivity:
NAAT (nucleic acid amplification test) can be an alternative to standard culture in the antepartum period, when a selective enrichment incubation step of 18–24 hours is performed. However, rapid NAAT in the intrapartum period is not routinely recommended as a replacement for antepartum culture/risk assessment: without enrichment, its sensitivity is low, sensitivity testing cannot be performed, and 7–10% test failure has been reported (UpToDate 2026).
Two groups are exempt from culture at 36–37 weeks because they will receive IAP regardless of the result (but they still receive IAP):
Caution: patients with only a positive GBS culture in a previous pregnancy, without an infant with EOGBS, should have a repeat culture in each pregnancy, because 50–60% are not colonized in the subsequent pregnancy (UpToDate 2026).
Antibiotics are administered intrapartum, not when culture positivity is detected; because administration of antibiotics away from birth does not eliminate colonization at the time of birth, when the baby is at risk for vertical transmission. Intravenous access is mandatory for the rapid passage of high maternal serum concentrations from the placenta to the fetal circulation and amniotic fluid; oral and intramuscular routes are not recommended (ACOG CO 797, 2020). Table 1 below summarizes the indications for IAP and situations in which prophylaxis is not recommended.
| IAP RECOMMENDED | IAP NOT RECOMMENDED |
|---|---|
| • Vaginal or rectal GBS screening culture positive • History of infant with EOGBS disease in previous pregnancy • GBS bacteriuria (any colony count) in current pregnancy • Unknown culture status + at least one risk factor: – Intrapartum fever ≥38 °C (≥100.4 °F) – Preterm labor (<37 0/7 weeks) – Preterm premature rupture of membranes – Prolonged membrane rupture (≥18 hours) – Intrapartum NAAT positive | • A negative culture at 36–37 weeks in the current pregnancy (or ≤5 weeks before birth)—even if risk factors are present* • Planned cesarean delivery (intact membranes, labor has not begun)—at any gestational age, even if GBS-positive • A positive culture in a previous pregnancy but a negative culture in the current pregnancy • Unknown status + no risk factors + negative rapid NAAT |
*If there is clinical evidence of chorioamnionitis, broad-spectrum antibiotics (containing an agent effective against GBS) are indicated for treatment, not prophylaxis.
For pregnant women with unknown antepartum culture status and a history of GBS colonization in a previous pregnancy but who do not have any of the above indications, ACOG considers it reasonable to recommend IAP through shared decision-making—but keep in mind that cultures from a previous pregnancy are not predictive of status at birth.
GBS; sensitive to penicillin G, ampicillin, cephalosporins and vancomycin; however, penicillin G is the most active and narrowest spectrum agent in vitro and is the first-line choice. Despite more than 25 years of widespread use, no confirmed resistant GBS isolates to penicillin, ampicillin, or cefazolin have been observed (UpToDate 2026). In contrast, in US surveillance data (2015–2017), erythromycin resistance is 55% and clindamycin resistance is 44%; therefore erythromycin is not recommended for prophylaxis.
First-line regimens:
IAP is most effective when administered ≥4 hours before birth. In a landmark study, the rate of neonatal colonization in newborns of colonized mothers was 46% when ampicillin was given <1 hour before birth, 29% 1–2 hours before, 2.9% 2–4 hours before, and only 1.2% when >4 hours before (rate 47% without prophylaxis) (UpToDate 2026). Antibiotics are usually started at the onset of labor or on hospitalization after membrane rupture and continued every 4 hours until birth.
Important: ACOG recognizes that shorter durations (e.g., 2 hours) are less effective than 4 hours, but emphasizes that medically/obstetrically necessary interventions should not be delayed solely to ensure a 4-hour antibiotic window (ACOG CO 797, 2020). Emergency caesarean section should not be delayed for ≥4 hours of prophylaxis.
The approach to pregnant women with a history of penicillin allergy is determined according to whether the anamnesis suggests a low or high risk for anaphylaxis (or the skin test result). This distinction is critical: misclassification leads to either unnecessary use of broad-spectrum/less effective antibiotics or the risk of anaphylaxis. Table 2 summarizes the algorithm.
In GBS-positive patients with severe (high risk for anaphylaxis) penicillin allergy who are candidates for IAP, the laboratory should test clindamycin susceptibility; To ensure this, allergy should be noted on the laboratory request form. If possible, both clindamycin and erythromycin susceptibility are studied: an erythromycin-resistant isolate may carry inducible resistance to clindamycin (D-zone test) even if it appears susceptible in the standard test.
| Clinical situation | Antibiotic and dosage (IV, until birth) |
|---|---|
| No allergy | Penicillin G 5 million U loading → 2.5–3 million U every 4 hours (sub.: Ampicillin 2 g → 1 g every 4 hours) |
| Low risk of anaphylaxis (isolated maculopapular rash, isolated headache/GI complaints; no urticaria/IgE findings) | Cefazolin 2 g loading → 1 g every 8 hours |
| High risk of anaphylaxis + susceptible to clindamycin (history of anaphylaxis/angioedema/urticaria; isolate susceptible to clindamycin and D-zone negative) | Clindamycin 900 mg every 8 hours |
| High risk + clindamycin resistant / susceptibility unknown / high risk isolate | Vancomycin — ACOG: 20 mg/kg (single dose max. 2 g) every 8 hours (normal renal function)* |
*UpToDate authors use the 2 g loading → 1 g every 12 hours (max. 4 g/day) regimen as an alternative due to nephrotoxicity concerns; However, it also states that the weight-based 20 mg/kg/8 hour regimen more reliably reaches therapeutic levels in neonatal cord blood. Vancomycin minimum infusion time ≥1 hour (≥500 mg/30 min for doses >1 g).
Role of skin test: Penicillin skin test is safe during pregnancy in pregnant women with a history of penicillin allergy and can clarify the allergic situation and prevent unnecessary use of alternative antibiotics. If a type I hypersensitivity reaction does not occur, penicillin alternatives are not needed; these patients are recommended to be challenged with a single dose of oral penicillin (usually amoxicillin) to confirm safe future use (UpToDate 2026).
GBS status in preterm labor is often unknown (since screening is performed at 36–37 weeks). If the colonization status is unknown, a GBS test is taken and prophylaxis is started if the newborn is potentially viable. In true preterm labor, prophylaxis is continued until birth; If it is thought that there is no true labor after observation, it is stopped. In preterm PROM, the antibiotic regimen given during the latency period should also include effective prophylaxis against GBS after the GBS sample is collected and should typically be given for 7 days and then discontinued; If the patient subsequently goes into labor, standard intrapartum GBS prophylaxis is administered.
Patients who are GBS-positive at term and whose membranes rupture before labor begins are referred to the hospital so that prophylaxis can be initiated. GBS colonization is not an indication for cesarean section. Since the risk of GBS transmission is very low in planned cesarean sections where labor has not started and the membranes are intact, prophylaxis is not required — these patients should nevertheless be screened at 36–37 weeks in case labor or membrane rupture occurs before the planned cesarean section. Emergency cesarean delivery should not be delayed to achieve ≥4 hours of prophylaxis (UpToDate 2026; ACOG CO 797, 2020).
Maternal intrapartum GBS chemoprophylaxis resulted in an over 80% reduction in EOGBS cases and a significant reduction in neonatal death. A 2014 Cochrane meta-analysis (Ohlsson & Shah, CD007467) showed that prophylaxis resulted in an 80% reduction in early neonatal GBS infection compared with no treatment (OR 0.17, 95% CI 0.04–0.74); however, the reduction in neonatal mortality did not reach statistical significance and the methodological quality of the studies reviewed was limited (high risk of bias)—this should be clearly noted in terms of the level of evidence.
The program has persistent limitations: a significant proportion of cases cannot be prevented due to culture false-negative (~4% of pregnant women screened in the 35–37 week protocol), lack of screening, or because the woman went into labor too late to provide the optimal time for prophylaxis. In a large retrospective study of more than 104,000 infants, the incidence of EOGBS sepsis in infants of GBS-positive mothers receiving first-line antibiotics (penicillin/ampicillin) was 0.10%, compared with 0.33% on other antibiotics and 0.34% in those receiving no antibiotics—highlighting the importance of proper agent selection (UpToDate 2026).
This section adds new and changed information for the period 2024–2026 to the existing guidance; The screening window (36 0/7–37 6/7 weeks), intrapartum antibiotic prophylaxis (IAP) indications, dosage schedules, and penicillin allergy algorithm did not change during this period.
Guideline status confirmation: a supersession check was performed for ACOG Committee Opinion No. 797 (February 2020); As of 2026, a new replacement Practice Bulletin/Clinical Practice Guideline has not been published and the document remains in effect with the approval of the AAP, ACNM, AWHONN, and SMFM (ACOG CO 797, 2020). CDC continues to direct its own clinical guidance to ACOG 2020; The current algorithm is up to date.
Commissioned by WHO/HRP to update peripartum infection recommendations, this PROSPERO-registered (CRD42023411806), ROBINS-I-assessed and GRADEd systematic review + meta-analysis provides the largest body of data in this field, with 72 observational studies, 20 countries and over 10 million live births (Prins et al., eClinicalMedicine 2024; PMID 39569026). In early-onset GBS (EOGBS) disease, any strategy reduces risk compared to no strategy (RR 0.46, 95% CI 0.36–0.60). In direct comparison, universal screening was significantly superior to the risk-based strategy (RR 0.41, 0.30–0.55; 17 studies). Two clinically important points: universal screening does not lead to more antibiotic use (risk-based 16% vs universal 21%; RR 1.29, 0.95–1.75) and, contrary to previous concern, early non-GBS sepsis was not increased but decreased with either strategy. Mortality due to EOGBS decreased by more than half (0.089 → 0.028/1000). No resistance was detected in first-line agents (penicillin, ampicillin, other β-lactams) (11 studies); Resistance was seen only in erythromycin/clindamycin, which is used in penicillin allergy, but not in vancomycin. The evidence is observational, moderate certainty (GRADE).
The cluster-randomized GBS3 trial (ISRCTN49639731), conducted in England/Wales with 80 maternity units and approximately 320,000 pregnant women, is the first randomized evidence comparing the clinical and cost-effectiveness of universal screening (antepartum + intrapartum NAAT) with the current risk-based strategy; All data to date has been observational. In process/feasibility results published in February 2026, 72% of women were offered a swab, 82% of those recommended accepted, 17% were GBS positive, and 87% had the result ready at least 4 hours before birth (Daniels et al., Early Hum Dev 2026; PMID 41325655). Primary clinical results are expected in late spring 2026 and may influence international guidelines.
The statement "vaccines are in development" in the current guidance has now become concrete. Pfizer's conjugate vaccine GBS6, covering six serotypes (Ia, Ib, II, III, IV, V; ~98% of global GBS disease), demonstrated strong antibody response and effective transplacental transmission in the pregnant woman in Phase 2 (Madhi et al., NEJM 2023;389:215–227); The global Phase 3 regulatory study BEATRIX started in 2024–2025 (NCT07160244). Modeling predicts that maternal vaccination could prevent more than half of infant GBS cases, as well as reduce preterm and stillbirth. WHO states that the first maternal GBS vaccines may become available in approximately 2030, but the vaccine is not yet in routine use (WHO GBS fact sheet, 24 April 2026).
In terms of global authority, the WHO 2024 guideline also recommends universal antenatal screening at 35–37 weeks where applicable and IV penicillin/ampicillin at least 4 hours before birth in positive cases (~80% reduction in EOGBS risk), keeping the risk-based approach as an alternative where universal screening is not applicable. There has been no change in the approach to cefazolin in low-risk penicillin allergy, clindamycin in high-risk sensitive cases, and vancomycin in high-risk clindamycin-resistant cases in 2024–2026; Evidence from the new meta-analysis that clindamycin may be poorer than ampicillin in preventing vertical transmission reinforces the penicillin/ampicillin priority.
Last updated: . Guide numbers and publication years have been verified against current catalogues.